Related references
Note: Only part of the references are listed.How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery?
Oriana Petruolo et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up
Sabrina Kahler-Ribeiro-Fontana et al.
EJSO (2021)
Patterns of axillary staging and management in clinically node positive breast cancer patients treated with neoadjuvant systemic therapy: Results of a survey amongst breast cancer specialists
J. M. Simons et al.
EJSO (2020)
Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy
Sanaz Samiei et al.
ANNALS OF SURGERY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
HER2-Low Breast Cancer: Pathological and Clinical Landscape
Paolo Tarantino et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Oncologic Outcomes of Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer
Mara A. Piltin et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Impact of modern-day axillary treatment on patient reported arm morbidity and physical functioning in breast cancer patients
Madelijn L. Gregorowitsch et al.
RADIOTHERAPY AND ONCOLOGY (2019)
Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer with axillary node metastasis: A survey of clinical practice
Sae Byul Lee et al.
ASIAN JOURNAL OF SURGERY (2019)
Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype
Rosa Di Micco et al.
EJSO (2019)
Heterogeneous Responses of Axillary Lymph Node Metastases to Neoadjuvant Chemotherapy are Common and Depend on Breast Cancer Subtype
Antonia Glaeser et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure
M. E. M. van der Noordaa et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial
Guido Henke et al.
TRIALS (2018)
Impact of Neoadjuvant Chemotherapy on Nodal Disease and Nodal Surgery by Tumor Subtype
Zahraa Al-Hilli et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Outcome after neoadjuvant chemotherapy in Asian breast cancer patients
Li Yan Lim et al.
CANCER MEDICINE (2017)
Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety
Ikuko Sugitani et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2017)
Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery
Audree B. Tadros et al.
JAMA SURGERY (2017)
Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members
Abigail S. Caudle et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study
Anita Mamtani et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)
Mehra Golshan et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment
V. Galimberti et al.
EJSO (2016)
Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection
Abigail S. Caudle et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Trastuzumab-Related Cardiotoxic Effects in Taiwanese Women A Nationwide Cohort Study
Hsu-Chih Chien et al.
JAMA ONCOLOGY (2016)
Marking Axillary Lymph Nodes With Radioactive Iodine Seeds for Axillary Staging After Neoadjuvant Systemic Treatment in Breast Cancer Patients The MARI Procedure
Mila Donker et al.
ANNALS OF SURGERY (2015)
Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base
Brigid K. Killelea et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study
Jean-Francois Boileau et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy
Tari A. King et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer Findings From the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial
Judy C. Boughey et al.
ANNALS OF SURGERY (2014)
Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial
Judy C. Boughey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study
Thorsten Kuehn et al.
LANCET ONCOLOGY (2013)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
The Role of Lymphovascular Invasion as a Prognostic Factor in Patients with Lymph Node-Positive Operable Invasive Breast Cancer
Young Ju Song et al.
JOURNAL OF BREAST CANCER (2011)
Cytologically Proven Axillary Lymph Node Metastases Are Eradicated in Patients Receiving Preoperative Chemotherapy With Concurrent Trastuzumab for HER2-Positive Breast Cancer
Laura S. Dominici et al.
CANCER (2010)
Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy
Peter H. O'Donnell et al.
CLINICAL CANCER RESEARCH (2009)
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
A. D. Barker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy for Advanced Breast Cancer: Results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French Prospective Multicentric Study
Jean-Marc Classe et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer Patients
Kelly K. Hunt et al.
ANNALS OF SURGERY (2009)
Prevalence of Lymphedema in Women With Breast Cancer 5 Years After Sentinel Lymph Node Biopsy or Axillary Dissection: Patient Perceptions and Precautionary Behaviors
Sarah A. McLaughlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons oncology Group trial Z0011
Anthony Lucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy
BT Hennessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
